Crosstalk between autophagy and apoptosis in initiating antitumor immune responses in human lymphoma cells

Abstract

Aim:Despite advances in lymphoma treatment, resistance to conventional therapies and insufficient immune-mediated tumor clearance remain major challenges. This study investigates the dual antitumor mechanisms of the mushroom-derived triterpenoid, ganoderic acid DM (GA-DM), exploring its ability to induce programmed cell death while enhancing immune recognition in diffuse large B-cell lymphoma (DLBCL).

Methods:DLBCL cells (DB and Toledo) were treated with GA-DM (0–40 μM), and cell viability was assessed via MTS assay. Apoptosis was evaluated through caspase-3 activation and inhibition by ZVAD-FMK, while autophagy was measured via LC3 protein expression. Flow cytometry analyzed HLA class II surface expression and antigen presentation to CD4⁺ T cells (via IL-2 production), with autophagy’s role further confirmed using the inhibitor 3-MA.

Results:GA-DM exhibited potent and dose-dependent cytotoxicity against DLBCL cells, with concentrations of 30–40 μM inducing over 60% cell death within 24 h. Mechanistic studies revealed that GA-DM activated the intrinsic apoptotic pathway, as evidenced by caspase-3 cleavage and the significant reduction in cell death upon ZVAD-FMK treatment. Concurrently, GA-DM treatment upregulated the autophagy marker LC3-II, indicating the induction of autophagy. Strikingly, GA-DM also enhanced the immunogenicity of lymphoma cells by increasing surface expression of HLA class II molecules. This led to improved antigen presentation and subsequent activation of CD4⁺ T cells, as demonstrated by a 2.5-fold increase in IL-2 production (amount of IL-2 in pg/mL) compared to untreated controls. The critical role of autophagy in this process was confirmed by the near-complete abrogation of HLA class II-mediated T-cell activation upon 3-MA treatment.

Conclusions:GA-DM synergistically induces apoptosis and autophagy while promoting immune-mediated tumor clearance through enhanced HLA class II antigen presentation. These findings highlight GA-DM as a promising multi-modal therapeutic candidate for lymphoma immunotherapy.

Keywords

triterpenoid / autophagy / apoptosis / crosstalk / HLA class II / CD4+ T cells / immune recognition

References

[1] Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005; 5: 251-62.

[2] Shaffer AL 3rd, Young RM, Staudt LM. Pathogenesis of Human B Cell Lymphomas. Annu Rev Immunol. 2012; 30: 565-610.

[3] Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017; 390: 298-310.

[4] Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019; 94: 604-16.

[5] Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018; 50: 74-87.

[6] Ayyappan S, Maddocks K. Correction to: Novel and emerging therapies for B cell lymphoma. J Hematol Oncol. 2021; 14: 28.

[7] Denlinger N, Bond D, Jaglowski S. CAR T-cell therapy for B-cell lymphoma. Curr Probl Cancer. 2022; 46: 100826.

[8] Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014; 11: 12-23.

[9] Candelaria M, Dueñas-Gonzalez A. Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. Ther Adv Hematol. 2021; 12: 2040620721989579.

[10] Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023; 20: 359-71.

[11] Mishra AP, Salehi B, Sharifi-Rad M, Pezzani R, Kobarfard F, Sharifi-Rad J, et al. Programmed Cell Death, from a Cancer Perspective: An Overview. Mol Diagn Ther. 2018; 22: 281-95.

[12] Ford CA, Petrova S, Pound JD, Voss JJ, Melville L, Paterson M, et al. Oncogenic Properties of Apoptotic Tumor Cells in Aggressive B Cell Lymphoma. Curr Biol. 2015; 25: 577-88.

[13] Kiraz Y, Adan A, Kartal Yandim M, Baran Y. Major apoptotic mechanisms and genes involved in apoptosis. Tumour Biol. 2016; 37: 8471-86.

[14] Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022; 12: 985363.

[15] Yoshida GJ. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. J Hematol Oncol. 2017; 10: 67.

[16] Das CK, Mandal M, Kögel D. Pro-survival autophagy and cancer cell resistance to therapy. Cancer Metastasis Rev. 2018; 37: 749-66.

[17] Djavaheri-Mergny M, Giuriato S, Tschan MP, Humbert M. Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma. Cells. 2019; 8: 103.

[18] Towers CG, Wodetzki D, Thorburn A. Autophagy and cancer: Modulation of cell death pathways and cancer cell adaptations. J Cell Biol. 2020; 219: e201909033.

[19] Yun CW, Lee SH. The Roles of Autophagy in Cancer. Int J Mol Sci. 2018; 19: 3466.

[20] D’Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019; 43: 582-92.

[21] Das S, Shukla N, Singh SS, Kushwaha S, Shrivastava R. Mechanism of interaction between autophagy and apoptosis in cancer. Apoptosis. 2021; 26: 512-33.

[22] Bata N, Cosford NDP. Cell Survival and Cell Death at the Intersection of Autophagy and Apoptosis: Implications for Current and Future Cancer Therapeutics. ACS Pharmacol Transl Sci. 2021; 4: 1728-46.

[23] Johnstone C, Chaves-Pozo E. Antigen Presentation and Autophagy in Teleost Adaptive Immunity. Int J Mol Sci. 2022; 23: 4899.

[24] Münz C. Autophagy Beyond Intracellular MHC Class II Antigen Presentation. Trends Immunol. 2016; 37: 755-63.

[25] Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, et al. How do CD4⁺ T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Front Immunol. 2014; 5: 174.

[26] Bawden E, Gebhardt T. The multifaceted roles of CD4⁺ T cells and MHC class II in cancer surveillance . Curr Opin Immunol. 2023; 83: 102345.

[27] Kilian M, Sheinin R, Tan CL, Friedrich M, Krämer C, Kaminitz A, et al. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer Cell. 2023; 41: 235-51.e9.

[28] Seliger B, Kloor M, Ferrone S. HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. Oncoimmunology. 2017; 6: e1171447.

[29] Axelrod ML, Cook RS, Johnson DB, Balko JM. Biological Consequences of MHC-II Expression by Tumor Cells in Cancer. Clin Cancer Res. 2019; 25: 2392-402.

[30] Bryant JM, Bouchard M, Haque A. Anticancer Activity of Ganoderic Acid DM: Current Status and Future Perspective. J Clin Cell Immunol. 2017; 8: 535.

[31] Zhao D, Hajiaghamohseni LM, Liu X, Szulc ZM, Bai A, Bielawska A, et al. Inhibition of acid ceramidase regulates MHC class II antigen presentation and suppression of autoimmune arthritis. Cytokine. 2020; 135: 155219.

[32] God JM, Zhao D, Cameron CA, Amria S, Bethard JR, Haque A. Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47000 MW acid labile protein in CD4⁺ T-cell recognition . Immunology. 2014; 142: 492-505.

[33] Amria S, Cameron C, Stuart R, Haque A. Defects in HLA class II antigen presentation in B-cell lymphomas. Leuk Lymphoma. 2008; 49: 353-5.

[34] Haque MA, Hawes JW, Blum JS. Cysteinylation of MHC class II ligands: peptide endocytosis and reduction within APC influences T cell recognition. J Immunol. 2001; 166: 4543-51.

[35] Haque MA, Li P, Jackson SK, Zarour HM, Hawes JW, Phan UT, et al. Absence of γ-Interferon-inducible Lysosomal Thiol Reductase in Melanomas Disrupts T Cell Recognition of Select Immunodominant Epitopes. J Exp Med. 2002; 195: 1267-77.

[36] Hathaway-Schrader JD, Norton D, Hastings K, Doonan BP, Fritz ST, Bethard JR, et al. GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition. Int J Mol Sci. 2022; 23: 1066.

[37] Hossain A, Radwan FF, Doonan BP, God JM, Zhang L, Bell PD, et al. A possible cross-talk between autophagy and apoptosis in generating an immune response in melanoma. Apoptosis. 2012; 17: 1066-78.

[38] Radwan FF, Hossain A, God JM, Leaphart N, Elvington M, Nagarkatti M, et al. Reduction of Myeloid-Derived Suppressor Cells and Lymphoma Growth by a Natural Triterpenoid. J Cell Biochem. 2015; 116: 102-14.

[39] Zhao D, Amria S, Hossain A, Sundaram K, Komlosi P, Nagarkatti M, et al. Enhancement of HLA class II-restricted CD4⁺ T cell recognition of human melanoma cells following treatment with bryostatin-1 . Cell Immunol. 2011; 271: 392-400.

[40] Radwan FF, Zhang L, Hossain A, Doonan BP, God JM, Haque A. Mechanisms regulating enhanced human leukocyte antigen class II-mediated CD4⁺ T cell recognition of human B-cell lymphoma by resveratrol . Leuk Lymphoma. 2012; 53: 305-14.

[41] Goldstein OG, Hajiaghamohseni LM, Amria S, Sundaram K, Reddy SV, Haque A. Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma. Cancer Immunol Immunother. 2008; 57: 1461-70.

[42] God JM, Cameron C, Figueroa J, Amria S, Hossain A, Kempkes B, et al. Elevation of c-MYC Disrupts HLA Class II-Mediated Immune Recognition of Human B Cell Tumors. J Immunol. 2015; 194: 1434-45.

[43] Younger AR, Amria S, Jeffrey WA, Mahdy AE, Goldstein OG, Norris JS, et al. HLA class II antigen presentation by prostate cancer cells. Prostate Cancer Prostatic Dis. 2008; 11: 334-41.

[44] Doonan BP, Radwan FFY, Banik NL, Haque A. Using a Natural Triterpenoid to Unlock the Antitumor Effects of Autophagy in B-Cell Lymphoma. Biomedicines. 2025; 13: 445.

[45] Nagai H, Kim YH. Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis. 2017; 9: 448-51.

[46] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229-63.

[47] Global Burden of Disease Cancer Collaboration. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022; 8: 420-44.

[48] Liu J, Bai Y, Li Y, Li X, Luo K. Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective. EBioMedicine. 2024; 107: 105301.

[49] Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther. 2021; 6: 72.

[50] Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020; 20: 651-68.

[51] Wang G, Jiang X, Torabian P, Yang Z. Investigating autophagy and intricate cellular mechanisms in hepatocellular carcinoma: Emphasis on cell death mechanism crosstalk. Cancer Lett. 2024; 588: 216744.

[52] Metur SP, Klionsky DJ. Adaptive immunity at the crossroads of autophagy and metabolism. Cell Mol Immunol. 2021; 18: 1096-105.

[53] Schmid D, Münz C. Innate and Adaptive Immunity through Autophagy. Immunity. 2007; 27: 11-21.

[54] Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M. Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol. 2023; 149: 8131-41.

[55] Ghemrawi R, Abuamer L, Kremesh S, Hussien G, Ahmed R, Mousa W, et al. Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy. Biomedicines. 2024; 12: 2158.

[56] Eskandari E, Eaves CJ. Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis. J Cell Biol. 2022; 221: e202201159.

[57] Lauwerys L, Beroske L, Solania A, Vangestel C, Miranda A, Van Giel N, et al. Development of caspase-3-selective activity-based probes for PET imaging of apoptosis. EJNMMI Radiopharm Chem. 2024; 9: 58.

[58] Botbol Y, Guerrero-Ros I, Macian F. Key roles of autophagy in regulating T-cell function. Eur J Immunol. 2016; 46: 1326-34.

[59] Jiang G, Tan Y, Wang H, Peng L, Chen HT, Meng XJ, et al. The relationship between autophagy and the immune system and its applications for tumor immunotherapy. Mol Cancer. 2019; 18: 17.

[60] Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020; 17: 395-417.

[61] Yun CW, Jeon J, Go G, Lee JH, Lee SH. The Dual Role of Autophagy in Cancer Development and a Therapeutic Strategy for Cancer by Targeting Autophagy. Int J Mol Sci. 2020; 22: 179.

[62] Mele L, Del Vecchio V, Liccardo D, Prisco C, Schwerdtfeger M, Robinson N, et al. The role of autophagy in resistance to targeted therapies. Cancer Treat Rev. 2020; 88: 102043.

[63] Peng F, Liao M, Qin R, Zhu S, Peng C, Fu L, et al. Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduct Target Ther. 2022; 7: 286.

[64] Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, et al. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Front Immunol. 2017; 8: 292.